Neointimal hyperplasia is a major cause of early restenosis after intervention in the cardiovascular system. For example, restenosis secondary to neointimal hyperplasia occurs in up to 50% of patients ...

The different effects of short- and long-term inhibition of another downstream regulator of SMC proliferation, c- myc, on neointimal formation in rats were recently reported by Edelman et al. 43 In ...

Objective: To analyse the neointimal coverage of sirolimus-eluting stent (SES) and bare-metal stent (BMS) visualised in vivo by optical coherence tomography (OCT). Methods: OCT images were obtained in ...

Neointimal hyperplasia is a known complication following aorta interventions. In this study, our hypothesis was that inhibiting phosphoglycerate kinase 1 (PGK1) could effectively reduce aortic ...

Unfortunately, all of these procedures injure the vascular endothelium, which impairs its ability to produce nitric oxide (NO) and ultimately leads to neointimal hyperplasia and restenosis.

At 6 months, less neointimal hyperplasia was found at both the proximal and distal anastomoses. This included the prosthetic wall, suture region, and arterial wall.

The link between cytoskeletal actin dynamics and correlated gene activities was unclear. However, the discovery that globular actin polymerization liberates myocardin family transcriptional ...

The newly formed neointimal lesions consist of both SMC and foam cell-like macrophages. Here we assessed the hypothesis that the use of potent anti-restenotic drugs, like sirolimus and paclitaxel, may ...

Introduction Vascular injury leads to the initiation and progression of atherosclerotic vascular disease and may result in neointimal hyperplasia, in-stent restenosis, and acute stent thrombosis ...

In recent years, there has been increasing interest in studying gut microbiome-derived hydrolases in relation to oral drug metabolism, particularly focusing on natural product drugs. Despite the ...